Federal Grantmaking Faces Overhaul: What It Could Mean For MI's Research and Innovation Economy

The Trump administration is advancing one of the most significant restructurings of the federal grantmaking system in decades, proposing changes that would dramatically alter how research funding is reviewed, awarded, monitored, and potentially terminated across the federal government. 

The 400-page proposal, released by the Office of Management and Budget (OMB), builds on President Trump's 2025 Executive Order, Improving Oversight of Federal Grantmaking, and would affect virtually every federal agency that distributes grants, including the National Institutes of Health (NIH), National Science Foundation (NSF), Department of Energy (DOE), Department of Defense (DoD), and numerous other agencies that support research, innovation, workforce development, and technology commercialization. 

While administration officials describe the effort as a necessary modernization intended to improve accountability, reduce waste, and ensure taxpayer dollars align with national priorities, researchers, universities, and scientific organizations are warning that the changes could fundamentally alter the longstanding peer-review system that has guided U.S. research funding for generations. 

What Would Change?

The proposed reforms go well beyond routine grant administration. They would introduce new layers of political oversight and expand federal authority over grants throughout their entire lifecycle. 

• Political Appointees Would Gain Final Review Authority 

Perhaps the most consequential change is the requirement that senior political appointees review funding opportunity announcements and discretionary grant awards before they are issued. 

Under the current system, grant applications are typically evaluated by subject matter experts and scientific peer-review panels, with agency program officials making final recommendations based largely on technical merit and programmatic fit. The proposed framework would add a political review layer designed to ensure awards align with administration priorities and agency objectives. 

Critics argue this could shift decision-making authority away from independent scientific reviewers and toward political leadership, potentially introducing greater uncertainty into funding decisions. 

• Expanded Authority to Terminate Existing Grants 

The proposal also directs agencies to incorporate stronger "termination for convenience" provisions into grant agreements. 

In practical terms, this would make it easier for agencies to cancel grants that are deemed inconsistent with agency priorities or no longer aligned with administration objectives, even after funding has already been awarded. Agencies would also be required to review existing grant portfolios and assess whether projects continue to support federal priorities. 

For researchers managing multi-year projects, the prospect of midstream termination is generating significant concern. Scientific studies often require years of continuous funding, particularly in biomedical research, clinical trials, advanced manufacturing, energy technologies, and other long-term research programs. 

• Greater Scrutiny of Indirect Costs 

The administration is also directing agencies to place greater emphasis on indirect cost rates—the funds universities and research institutions receive to support facilities, laboratories, compliance functions, cybersecurity, utilities, and administrative infrastructure necessary to conduct federally funded research. 

The proposal encourages agencies to favor institutions with lower indirect cost rates and signals broader efforts to scrutinize overhead expenses associated with federal awards. 

Research universities argue that indirect costs are not administrative excess, but rather essential investments that allow research programs to operate safely and effectively. For major research institutions, reductions in indirect cost recovery can have substantial financial consequences. 

• New Performance and Compliance Requirements 

The proposed rule would expand federal monitoring requirements, increase oversight of grant performance, and require agencies to implement stronger controls designed to detect waste, fraud, and misuse of federal funds. 

Federal agencies would be expected to conduct more extensive reviews of grant outcomes, establish clearer performance metrics, and use federal data systems to monitor recipients. Political leadership would also have greater visibility into grant administration and program performance. 

Supporters contend these measures will improve accountability and ensure taxpayer dollars generate measurable public benefit. Critics worry the additional administrative burden could slow funding decisions and divert resources away from research activities. 

• Alignment With Presidential Priorities Becomes Explicit 

The proposed rule repeatedly emphasizes that federal grants should advance priorities established by the President and agency leadership. 

OMB argues that previous administrations allowed grants to support activities that did not sufficiently reflect authorized public purposes or national interests. The new framework would require agencies to demonstrate stronger alignment between grant programs and executive branch priorities. 

This provision has generated particular concern among academic institutions and scientific organizations because future funding decisions could become more vulnerable to political shifts between administrations. 

Why Researchers Are Alarmed 

Many researchers view the proposal not as a routine administrative reform but as a structural change to the relationship between science and government. 

Scientific organizations argue that the strength of the U.S. research enterprise has long depended on merit-based peer review, where proposals compete primarily on scientific quality, innovation potential, and likelihood of impact. They worry that introducing political review into funding decisions could discourage certain research areas, create uncertainty for investigators, and weaken confidence in the neutrality of the grantmaking process. 

These concerns are occurring against a backdrop of broader tensions surrounding federal research funding. Over the past year, researchers have reported delays in grant reviews, heightened scrutiny of certain research topics, and uncertainty surrounding funding priorities at several federal agencies. 

Why Michigan Has a Lot at Stake 

For Michigan, the implications extend far beyond university campuses. 

The state's research ecosystem depends heavily on federal investment. The University of Michigan, Michigan State University, Wayne State University, and numerous hospital systems, nonprofit research organizations, and startup support programs collectively receive hundreds of millions of dollars annually through NIH, NSF, DOE, DoD, and other federal agencies. 

Federal research funding also serves as the foundation of Michigan's commercialization pipeline. Many technologies that ultimately become startup companies, venture-backed innovations, licensed intellectual property, and new healthcare products begin as federally funded academic research projects. 

If grant reviews become slower, more politically driven, or more vulnerable to cancellation, Michigan institutions could face greater difficulty planning long-term research programs, recruiting top scientific talent, and attracting follow-on private investment. 

The state's growing life sciences sector may be particularly sensitive to these changes. Biomedical innovation often requires a decade or more of sustained research before discoveries reach patients. Greater uncertainty around federal funding could make those pathways more difficult to navigate. 

Looking Ahead 

The proposal is currently undergoing public review, and significant debate is expected among universities, research institutions, industry groups, and federal agencies before any final rule is implemented. 

Regardless of the final outcome, the proposal signals a major shift in federal thinking about research funding and grant oversight. For Michigan's research universities, healthcare systems, startups, and innovation organizations, the coming months could help define the future environment in which scientific discovery and technology commercialization occur. 

At a time when states are competing aggressively for talent, investment, and innovation leadership, the structure and stability of the federal research enterprise remain critical components of economic competitiveness. Michigan's research community should pay close attention as the debate unfolds.